Company profile for OSE Immunotherapeutics SA

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company utilizes several scientific and technological approaches including neoepitopes and agonist/antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Our first-in-class pipeline offers a diver...
OSE Immunotherapeutics is a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmmune diseases. The company utilizes several scientific and technological approaches including neoepitopes and agonist/antagonist monoclonal antibodies, all ideally positioned to fight cancer and autoimmune diseases. Our first-in-class pipeline offers a diversified risk profile, ranging from registrational to clinical stage to R&D.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
France
Address
Address
22, boulevard Benoni Goullin \n44200 Nantes
Telephone
Telephone
33 (0) 2 28 29 10 10
youtube
YouTube

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/12/08/3201201/0/en/OSE-Immunotherapeutics-Announces-Strategic-Amendment-to-AbbVie-s-Partnership-on-ABBV-230-Development.html

GLOBENEWSWIRE
09 Dec 2025

https://www.globenewswire.com/news-release/2025/11/17/3189428/0/en/OSE-Immunotherapeutics-Announces-Positive-Recommendation-from-Independent-Data-Monitoring-Committee-IDMC-to-Continue-Pivotal-Phase-3-ARTEMIA-Trial-Evaluating-Tedopi-in-Non-Small-Ce.html

GLOBENEWSWIRE
17 Nov 2025

https://www.globenewswire.com/news-release/2025/11/07/3183856/0/en/OSE-Immunotherapeutics-Presents-a-Poster-on-OSE-Cytomask-a-Novel-Cis-Demasking-Cytokine-Technology-to-Increase-Therapeutic-Index-of-Immunocytokines.html

GLOBENEWSWIRE
07 Nov 2025

https://www.globenewswire.com/news-release/2025/10/15/3167380/0/en/OSE-Immunotherapeutics-Reports-First-Half-2025-Financial-Results.html

GLOBENEWSWIRE
15 Oct 2025

https://www.globenewswire.com/news-release/2025/10/03/3160785/0/en/Appointment-of-Marc-Le-Bozec-as-Interim-CEO.html

GLOBENEWSWIRE
03 Oct 2025

https://www.globenewswire.com/news-release/2025/09/30/3158981/0/en/Full-renewal-of-the-Board-of-Directors-Election-of-Dr-Markus-Cappel-as-Chairman-of-the-Board-of-Directors.html

GLOBENEWSWIRE
30 Sep 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty